Direct acting antivirals therapy and hepatocellular carcinoma risk in patients with hepatitis C virus

• 作者: Monika Pazgan-Simon
• 来源期刊: 肝癌研究（英文版）
• 年，卷（期）: 2020,（4）
• 页码范围: 39-46
• 页数: 8页
• 语种: 英文
• DOI: 10.20517/2394-5079.2019.52

摘要

The estimated number of people with active hepatitis C virus infection worldwide is about 70 million. The estimated number of people with active hepatitis C virus infection worldwide is about 70 million. Approximately 30％ of infected individuals develop cirrhosis, whilst some develop liver cancer, the fifth most common cancer worldwide. Currently available treatments, high-efficacy antiviral agents mostly short-term (8-12 weeks) and pangenotypic, have efficacy rates of over 96％. Some patients, especially those with cirrhosis, develop primary liver cancer even after effective hepatitis C virus treatment. In order to diagnose hepatocellular carcinoma early, patients at risk should be enrolled in a surveillance program.